<DOC>
	<DOC>NCT01289886</DOC>
	<brief_summary>The objective of this study is to determine the safety and tolerability and to determine the Pharmacokinetic and Pharmacodynamic (PK/PD) of ascending single oral dose of BR-A-657 in healthy male subjects.</brief_summary>
	<brief_title>Fimasartan (BR-A-657) Single Oral Dose in Healthy Subjects</brief_title>
	<detailed_description>BR-A-657 20, 50, 120, 240, 360, 480mg or placebo were administered once to healthy male subjects. Pharmacokinetic and Pharmacodynamic(PK/PD) parameters were monitored at pre-specified times from each subjects. PK parameters: Area Under the Curve(AUC), Cmax, half-life, etc. PD parameters: Aldosterone, Plasma renin activity, Angiotensin I, Angiotensin II Adverse events are reported.</detailed_description>
	<criteria>male of 1855 years old Body Mass Index(BMI) 1929kg/m2 subjects in good health subjects with written informed consent subjects with multiple drug allergy or allergy to Angiotensin Receptor Blocker(ARB) subjects with medication that affect drug absorption or elimination within 30days. subjects with orthostatic hypotension of &gt;20mmHg decrease of Systolic Blood Pressure(SBP) subjects with history of neurologic, liver, renal, gastrointestinal, cardiovascular, psychological or other major disorder</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>single-dose</keyword>
	<keyword>pharmacokinetic</keyword>
	<keyword>pharmacodynamic</keyword>
	<keyword>safety</keyword>
</DOC>